Impact of gestrinone on the course of asymptomatic endometriosis.

Abstract

A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p = 0.002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p = 0.057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p = 0.004), confirming that gestrinone is an effective treatment of endometriosis. Endometriosis deteriorates in at least 23% of patients; as it is impossible to predict in whom this will happen, treatment appears to be warranted in all cases.

• Authors: E J Thomas, I D Cooke
• Journal: British medical journal (Clinical research ed.) (Br Med J (Clin Res Ed)) Vol. 294 Issue 6567 Pg. 272-4 (Jan 31 1987) ISSN: 0267-0623 [Print] England
• PMID: 3101839 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Norpregnatrienes
• Gestrinone

Topics

• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Endometriosis (drug therapy)
• Female
• Gestrinone (therapeutic use)
• Humans
• Norpregnatrienes (therapeutic use)
• Random Allocation